Related references
Note: Only part of the references are listed.Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
Christoph Male et al.
HAEMATOLOGICA (2021)
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
Barbara A. Konkle et al.
BLOOD (2021)
Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum
Juthakorn Poothong et al.
BLOOD (2020)
Engineering adeno-associated virus vectors for gene therapy
Chengwen Li et al.
NATURE REVIEWS GENETICS (2020)
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
Wolfgang Miesbach et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
The Immune Response to the fVIII Gene Therapy in Preclinical Models
Seema R. Patel et al.
FRONTIERS IN IMMUNOLOGY (2020)
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
Benjamin J. Samelson-Jones et al.
FRONTIERS IN IMMUNOLOGY (2020)
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates
Benjamin J. Samelson-Jones et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
K. John Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Benjamin J. Samelson-Jones et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs
Anna Majowicz et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Enhanced Factor IX Activity following Administration of AAV5-R338L Padua Factor IX versus AAV5 WT Human Factor IX in NHPs
Elisabeth A. Spronck et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Gene therapy for hemophilia
Amit C. Nathwani
Hematology-American Society of Hematology Education Program (2019)
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Annette Von Drygalski et al.
BLOOD ADVANCES (2019)
FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice
Simone Merlin et al.
BLOOD ADVANCES (2019)
Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice
Chunyan Gao et al.
BLOOD ADVANCES (2019)
Alloantibodies in von Willebrand Disease
Massimo Franchini et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2018)
High and long-term von Willebrand factor expression after Sleeping Beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease
I. Portier et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Platelet-Targeted Gene Therapy for Hemophilia
Qizhen Shi
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Pasqualina Colella et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults
John D. Grainger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Gene therapy for hemophilia: what does the future hold?
Bhavya S. Doshi et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model
Robert A. French et al.
BLOOD ADVANCES (2018)
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Divya S. Vinjamur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing Empty Viral Particles on Safety and Efficacy of Gene Transfer
Amit C. Nathwani et al.
BLOOD (2018)
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
Wolfgang Miesbach et al.
BLOOD (2018)
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Stephen Russell et al.
LANCET (2017)
A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice
Simone Merlin et al.
MOLECULAR THERAPY (2017)
In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model
Citra N. Z. Mattar et al.
MOLECULAR THERAPY (2017)
Integration site selection by retroviruses and transposable elements in eukaryotes
Tania Sultana et al.
NATURE REVIEWS GENETICS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools
Kasper Lamberth et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease
Yoshihide Sehara et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2017)
Advances in the diagnosis and treatment of Von Willebrand disease
Ruchika Sharma et al.
BLOOD (2017)
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII
Oscar A. Marcos-Contreras et al.
BLOOD (2016)
Men with severe hemophilia in the United States: birth cohort analysis of a large national database
Marshall A. Mazepa et al.
BLOOD (2016)
TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity
J. Mahlangu et al.
HAEMOPHILIA (2016)
Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies
T. C. Nichols et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Prophylaxis in von Willebrand Disease: Coming of Age?
Giorgia Saccullo et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)
Treatment of von Willebrand Disease
Jennifer Curnow et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)
New Insights Into the Treatment of Glanzmann Thrombasthenia
Man-Chiu Poon et al.
TRANSFUSION MEDICINE REVIEWS (2016)
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
Julie M. Crudele et al.
BLOOD (2015)
Rare bleeding disorders: diagnosis and treatment
Roberta Palla et al.
BLOOD (2015)
von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
Peter J. Lenting et al.
BLOOD (2015)
Long-term prophylaxis in severe factor VII deficiency
S. M. Siboni et al.
HAEMOPHILIA (2015)
Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial
Paul E. Monahan et al.
HUMAN GENE THERAPY (2015)
Intraosseous Delivery of Lentiviral Vectors Targeting Factor VIII Expression in Platelets Corrects Murine Hemophilia A
Xuefeng Wang et al.
MOLECULAR THERAPY (2015)
Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Alessio Cantore et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Life-threatening bleeding in factor VII deficiency: the role of prenatal diagnosis and primary prophylaxis
Roula Farah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
How it all starts: Initiation of the clotting cascade
Stephanie A. Smith et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Females with FVIII and FIX deficiency have reduced joint range of motion
Robert F. Sidonio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response
Margareth C. Ozelo et al.
BLOOD (2014)
A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII
Scot A. Fahs et al.
BLOOD (2014)
Murine coagulation factor VIII is synthesized in endothelial cells
Lesley A. Everett et al.
BLOOD (2014)
von Willebrand factor, Jedi knight of the bloodstream
Timothy A. Springer
BLOOD (2014)
Inhibitors to factor VII in congenital factor VII deficiency
A. Batorova et al.
HAEMOPHILIA (2014)
Severe and moderate haemophilia A and B in US females
D. M. Di Michele et al.
HAEMOPHILIA (2014)
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
S. R. Lentz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Genetic sequence analysis of inherited bleeding diseases
Flora Peyvandi et al.
BLOOD (2013)
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)
Mariasanta Napolitano et al.
HAEMATOLOGICA (2013)
Evaluating for Suspected Child Abuse: Conditions That Predispose to Bleeding
Shannon L. Carpenter et al.
PEDIATRICS (2013)
Glanzmann Thrombasthenia: State of the Art and Future Directions
Alan T. Nurden et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
Lily M. Du et al.
NATURE COMMUNICATIONS (2013)
AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage
Christopher Binny et al.
BLOOD (2012)
Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Alessio Cantore et al.
BLOOD (2012)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
George Buchlis et al.
BLOOD (2012)
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
Jonathan D. Finn et al.
BLOOD (2012)
In Vivo Gene Transfer Strategies to Achieve Partial Correction of von Willebrand Disease
Lan Wang et al.
HUMAN GENE THERAPY (2012)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Platelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogs
Juan Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Production, Purification and Characterization of Adeno-Associated Vectors
Eduard Ayuso et al.
CURRENT GENE THERAPY (2010)
Successful treatment of canine hemophilia by continuous expression of canine FVIIa
Paris Margaritis et al.
BLOOD (2009)
Effect of Adeno-Associated Virus Serotype and Genomic Structure on Liver Transduction and Biodistribution in Mice of Both Genders
Astrid Paneda et al.
HUMAN GENE THERAPY (2009)
Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency
Timothy C. Nichols et al.
ILAR JOURNAL (2009)
Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Valder R. Arruda et al.
MOLECULAR THERAPY (2009)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Paolo Simioni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Factor VII Deficiency
Guglielmo Mariani et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2009)
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease
Simon F. De Meyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants
Isabelle Marx et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Management of carriers and babies with haemophilia
A. M. Street et al.
HAEMOPHILIA (2008)
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
Steven J. Howe et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibitor development in haemophilia B: an orphan disease in need of attention
Donna DiMichele
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF
Peter J. Lenting et al.
BLOOD (2007)
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
Haiyan Jiang et al.
MOLECULAR THERAPY (2006)
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor
Simon F. De Meyer et al.
BLOOD (2006)
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response
CS Manno et al.
NATURE MEDICINE (2006)
High levels of persistent expression of (A-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses
BP De et al.
MOLECULAR THERAPY (2006)
Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia
J Fang et al.
BLOOD (2005)
Gene therapy for hemophilia: an imperative to succeed
C Hough et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy
LL Wang et al.
BLOOD (2005)
Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study
LC Petersen et al.
THROMBOSIS RESEARCH (2005)
Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway
AM Davidoff et al.
BLOOD (2003)
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
CS Manno et al.
BLOOD (2003)
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia
DA Wilcox et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
RW Herzog et al.
HUMAN GENE THERAPY (2002)
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation
RW Herzog et al.
MOLECULAR THERAPY (2001)
Posttranslational modifications of recombinant myotube-synthesized human factor IX
VR Arruda et al.
BLOOD (2001)
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
MA Kay et al.
NATURE GENETICS (2000)
Share Paper
